文献速递骨肌介入神经CTMR

经皮椎体骨内椎基底神经射频消融术治疗椎源性慢性下腰痛

Intra-osseous basivertebral nerve radiofrequency ablation (BVA) for the treatment of vertebrogenic chronic low back pain.
PubMed 文献 · Neuroradiology · 2020-10-13

前瞻性实验性非对照试验纳入56例椎源性慢性下腰痛患者,行CT引导下经皮椎基底神经射频消融术。3个月和12个月随访时VAS与ODI评分较基线显著下降,疼痛和功能障碍的临床成功率均为96.5%(54/56),CT引导靶向消融区成功率为100%,平均手术时间32分钟,未检测到即刻或延迟并发症。作者认为该技术似乎是安全、快速且有效的镇痛方法,患者选择需基于包括常规诊断放射学与核医学影像的多学科方法。

要点

  • CT引导下经皮椎基底神经射频消融术在56例椎源性慢性下腰痛患者中疼痛与功能障碍临床成功率均为96.5%(54/56)。
  • 3个月和12个月随访时VAS与ODI评分较基线显著下降,疼痛改善超过2 cm、功能障碍改善超过10分的MCID阈值。
  • 术后1个月MRI评估消融区,CT引导靶向消融区成功率为100%;术后3个月CT评估骨密度以排除治疗相关结构异常。

核心结论

  • 经皮CT引导下骨内椎基底神经射频消融术似乎是治疗椎源性慢性下腰痛的安全、快速且有效的镇痛技术,患者选择应基于包括常规诊断放射学与核医学影像的多学科方法。

研究设计与样本

  • 前瞻性实验性非对照试验,纳入56例连续就诊的椎源性慢性下腰痛患者,局部麻醉下使用可弯曲双极射频电极(STAR™ Tumor Ablation System Merit)行经皮CT引导下椎基底神经射频消融术。
  • 术后1个月行MRI评估消融区以判定靶向成功率,术后3个月行CT评估骨密度以排除治疗可能引起的结构骨异常。
  • 采用视觉模拟量表(VAS)和Oswestry功能障碍指数(ODI)测量术前与术后疼痛和功能障碍水平。

关键影像表现/征象

  • 术后1个月MRI用于评估消融区域,以判定手术靶向是否成功。
  • 术后3个月CT用于评估骨密度,以排除治疗可能诱发的结构性骨异常。
  • CT引导靶向消融区在100%的患者中被判定为成功。

诊断标准与关键数值

  • VAS评分改善≥2 cm设为临床成功阈值,ODI评分改善≥10分设为临床成功阈值。
  • 3个月和12个月随访时VAS与ODI评分较基线显著下降,超过MCID。
  • 疼痛临床成功率为54/56(96.5%),功能障碍临床成功率为54/56(96.5%)。
  • CT引导靶向消融区成功率为100%,平均手术时间32分钟。
  • 未检测到即刻或延迟并发症。

临床应用与阅片要点

  • 作者认为经皮CT引导下骨内椎基底神经射频消融术似乎是安全、快速且有效的镇痛技术,适用于经多学科方法(包括常规诊断放射学与核医学影像)选择的椎源性慢性下腰痛患者。
  • 术后1个月MRI可用于评估消融区域以判定靶向成功,术后3个月CT可用于评估骨密度以排除结构性骨异常。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

STUDY DESIGN: Prospective experimental uncontrolled trial.

BACKGROUND: Vertebrogenic pain is a frequently underestimated cause of chronic low back pain (LBP). Vertebral endplate degeneration, characterized by cortical bone damage and subchondral bone inflammatory reaction, is a significant source of LBP, the responsible of the pain transmission being the Basivertebral Nerve (BVN). Radiofrequency ablation of the BVN (BVA) leads to thermal injury of nerve tissue and interruption of the of chronic vertebrogenic pain transmission.

PURPOSE: The aim of this study is to evaluate the effectiveness, in terms of pain and disability reduction, of percutaneous (BVA) in treating patients affected by vertebrogenic chronic LBP. Moreover, as a secondary endpoint, the purpose is to assess the feasibility and safety of a percutaneous CT-guided technique.

METHODS: We performed percutaneous CT-guided BVN ablation in 56 consecutive patients presenting with vertebrogenic chronic LBP in local anesthesia using an articulating bipolar radiofrequency electrode (STAR™ Tumor Ablation System Merit). A 1-month follow-up MRI was performed to evaluate the ablation area in order to assess the target success of the procedure. A 3-month follow-up CT study was performed to evaluate bone mineral density in order to exclude structural bone abnormalities that might have been induced by the treatment. Pre- and post-procedure pain and disability levels were measured using the visual analogue scale (VAS) and Oswestry Disability Index (ODI). A 2-cm improvement threshold was set as clinical success for the VAS score and a 10-point improvement threshold was set as clinical success for the ODI score.

RESULTS: At 3- and 12-month follow-up, VAS and ODI scores decreased significantly compared to baseline. Clinical success was reached in 54/56 patients (96.5%) for pain and 54/56 patients (96.5%) for disability, exceeding significantly the MCID. CT-assisted targeting of the ablation zone was determined successful in 100% of patients. Mean operative time was 32 min. No immediate or delayed complications were detected.

CONCLUSIONS: Percutaneous CT-guided intra-osseous BVA seems to be a safe, fast, and powerful technique for pain relief in patients with vertebrogenic chronic LBP, when the selection of patients is based on a multidisciplinary approach including both conventional Diagnostic Radiology and Nuclear Medicine imaging.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. De Vivo AE, D'Agostino G, D'Anna G, et al. Intra-osseous basivertebral nerve radiofrequency ablation (BVA) for the treatment of vertebrogenic chronic low back pain. Neuroradiology. 2020. PMID: 33051706. doi:10.1007/s00234-020-02577-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。